E3 Ubiquitin Ligase TRIM Proteins, Cell Cycle and Mitosis.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
27 05 2019
Historique:
received: 03 05 2019
revised: 22 05 2019
accepted: 23 05 2019
entrez: 30 5 2019
pubmed: 30 5 2019
medline: 30 5 2019
Statut: epublish

Résumé

The cell cycle is a series of events by which cellular components are accurately segregated into daughter cells, principally controlled by the oscillating activities of cyclin-dependent kinases (CDKs) and their co-activators. In eukaryotes, DNA replication is confined to a discrete synthesis phase while chromosome segregation occurs during mitosis. During mitosis, the chromosomes are pulled into each of the two daughter cells by the coordination of spindle microtubules, kinetochores, centromeres, and chromatin. These four functional units tie chromosomes to the microtubules, send signals to the cells when the attachment is completed and the division can proceed, and withstand the force generated by pulling the chromosomes to either daughter cell. Protein ubiquitination is a post-translational modification that plays a central role in cellular homeostasis. E3 ubiquitin ligases mediate the transfer of ubiquitin to substrate proteins determining their fate. One of the largest subfamilies of E3 ubiquitin ligases is the family of the tripartite motif (TRIM) proteins, whose dysregulation is associated with a variety of cellular processes and directly involved in human diseases and cancer. In this review we summarize the current knowledge and emerging concepts about TRIMs and their contribution to the correct regulation of cell cycle, describing how TRIMs control the cell cycle transition phases and their involvement in the different functional units of the mitotic process, along with implications in cancer progression.

Identifiants

pubmed: 31137886
pii: cells8050510
doi: 10.3390/cells8050510
pmc: PMC6562728
pii:
doi:

Substances chimiques

Tripartite Motif Proteins 0
Ubiquitin 0
Ubiquitin-Protein Ligases EC 2.3.2.27

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

Chromosoma. 2016 Sep;125(4):645-59
pubmed: 27376724
Pharmacol Ther. 2018 May;185:12-25
pubmed: 29097306
Cell Mol Biol (Noisy-le-grand). 2017 May 20;63(5):68-74
pubmed: 28719348
Int J Oncol. 2016 Apr;48(4):1639-49
pubmed: 26892350
Biochim Biophys Acta. 2015 Feb;1853(2):409-21
pubmed: 25450970
Biosci Rep. 2017 Jul 12;37(4):
pubmed: 28620119
Sci Rep. 2016 Jul 14;6:29822
pubmed: 27412325
Oncol Rep. 2017 Jul;38(1):43-52
pubmed: 28534983
Lab Invest. 2016 Jan;96(1):37-48
pubmed: 26568293
Head Neck Pathol. 2020 Mar;14(1):239-245
pubmed: 30610524
DNA Repair (Amst). 2016 Jun;42:63-71
pubmed: 27156098
J Exp Clin Cancer Res. 2018 Jun 13;37(1):116
pubmed: 29898761
Nat Cell Biol. 2009 Jan;11(1):65-70
pubmed: 19079246
J Biol Chem. 2004 Dec 24;279(52):54590-8
pubmed: 15485811
Oncogene. 2019 Jun;38(24):4657-4668
pubmed: 30783189
Oncotarget. 2016 Oct 4;7(40):64921-64931
pubmed: 27626314
Int J Clin Oncol. 2015 Jun;20(3):508-17
pubmed: 25345539
Int J Mol Sci. 2017 Sep 08;18(9):
pubmed: 28885545
Int J Oncol. 2018 Aug;53(2):620-632
pubmed: 29767249
J Exp Clin Cancer Res. 2019 Apr 12;38(1):159
pubmed: 30979374
J Cell Sci. 2018 Aug 16;131(16):
pubmed: 30115751
Cell. 2010 Nov 24;143(5):677-81
pubmed: 21111228
Oncol Res. 2017 Sep 21;25(8):1253-1259
pubmed: 28160462
Oncol Rep. 2016 Sep;36(3):1411-8
pubmed: 27430345
Cancer Cell Int. 2018 Dec 11;18:202
pubmed: 30555277
Oncol Lett. 2017 Apr;13(4):2649-2655
pubmed: 28454446
Cell Cycle. 2013 Mar 15;12(6):889-98
pubmed: 23422002
J Biomed Sci. 2017 Aug 29;24(1):63
pubmed: 28851455
Digestion. 2019 May 10;:1-10
pubmed: 31079111
J Exp Clin Cancer Res. 2016 Jun 21;35(1):100
pubmed: 27329103
Annu Rev Cell Dev Biol. 2003;19:141-72
pubmed: 14570567
Cancer Manag Res. 2018 Dec 05;10:6685-6693
pubmed: 30584363
Bioessays. 2005 Nov;27(11):1147-57
pubmed: 16237670
Cancer Res. 2018 Dec 15;78(24):6795-6806
pubmed: 30389700
Biology (Basel). 2017 Jan 24;6(1):
pubmed: 28125021
Cancer Res. 2014 Jul 15;74(14):3857-69
pubmed: 24860162
Int J Biol Sci. 2018 Nov 3;14(14):2073-2082
pubmed: 30585270
Cell Mol Life Sci. 2016 Sep;73(18):3497-506
pubmed: 27137187
JAKSTAT. 2013 Jul 1;2(3):e25408
pubmed: 24069565
J Biol Chem. 2006 Mar 31;281(13):8970-80
pubmed: 16434393
Med Sci Monit. 2018 Nov 09;24:8033-8041
pubmed: 30412518
Nat Rev Mol Cell Biol. 2003 Jun;4(6):491-7
pubmed: 12778128
Biochem Biophys Res Commun. 2018 Apr 6;498(3):686-692
pubmed: 29524410
Thorac Cancer. 2015 Jan;6(1):31-7
pubmed: 26273332
Sci Rep. 2016 Jan 12;6:19070
pubmed: 26754079
Gene. 2019 May 25;698:50-60
pubmed: 30822475
Mol Cell Oncol. 2015 Jan 30;2(1):e970484
pubmed: 27308407
Cell Rep. 2013 Jul 11;4(1):19-30
pubmed: 23831032
J Biochem. 2012 Feb;151(2):139-44
pubmed: 22023800
J Cell Commun Signal. 2018 Mar;12(1):21-29
pubmed: 29110249
Int J Clin Exp Pathol. 2015 May 01;8(5):5053-61
pubmed: 26191199
Cell Physiol Biochem. 2017;44(1):255-266
pubmed: 29190611
Oncotarget. 2017 Jan 10;8(2):2890-2905
pubmed: 27926516
Anticancer Res. 2018 Mar;38(3):1241-1245
pubmed: 29491046
Clin Genitourin Cancer. 2016 Aug;14(4):298-303
pubmed: 26873435
Med Sci Monit. 2019 May 07;25:3366-3373
pubmed: 31062766
Biochim Biophys Acta Gen Subj. 2019 Feb;1863(2):491-501
pubmed: 30528352
Oncotarget. 2017 Jul 7;9(13):10880-10890
pubmed: 29541383
Curr Biol. 2004 Nov 23;14(22):R953-5
pubmed: 15556852
Trends Cell Biol. 2017 May;27(5):314-321
pubmed: 28188027
Microbiol Mol Biol Rev. 2002 Jun;66(2):155-78
pubmed: 12040122
Biochem Biophys Res Commun. 2009 Apr 10;381(3):383-7
pubmed: 19232519
Int Rev Cell Mol Biol. 2017;328:105-161
pubmed: 28069132
Nucleic Acids Res. 2019 Jan 10;47(1):468-479
pubmed: 30407575
Cancer Sci. 2018 Oct;109(10):3080-3092
pubmed: 30098109
Pathol Res Pract. 2017 Oct;213(10):1271-1275
pubmed: 28916426
Mol Med Rep. 2016 Jun;13(6):5200-6
pubmed: 27121462
Cancer Manag Res. 2018 Nov 20;10:5951-5964
pubmed: 30538545
EMBO Rep. 2008 Jun;9(6):536-42
pubmed: 18516089
Oncol Lett. 2017 Aug;14(2):2125-2130
pubmed: 28781653
Biomed Pharmacother. 2019 Jan;109:595-601
pubmed: 30399596
Biomed Pharmacother. 2017 Dec;96:98-103
pubmed: 28965013
Oncol Rep. 2018 Dec;40(6):3273-3284
pubmed: 30272351
Environ Mol Mutagen. 2009 Oct;50(8):602-19
pubmed: 19774610
Med Oncol. 2014 Aug;31(8):102
pubmed: 24994609
Onco Targets Ther. 2017 Mar 09;10:1503-1512
pubmed: 28331343
Oncol Rep. 2019 Jun;41(6):3325-3334
pubmed: 31002351
Proc Natl Acad Sci U S A. 2007 Jun 5;104(23):9679-84
pubmed: 17535915
Genes Cancer. 2012 Nov;3(11-12):697-711
pubmed: 23634257
Cell Death Dis. 2017 May 25;8(5):e2831
pubmed: 28542145
Sci Rep. 2017 Feb 16;7:42411
pubmed: 28205534
Exp Cell Res. 2010 Feb 15;316(4):568-79
pubmed: 20006605
Trends Biochem Sci. 2017 Apr;42(4):297-311
pubmed: 28118948
Med Sci Monit. 2019 Jan 04;25:98-106
pubmed: 30608062
Trends Cardiovasc Med. 2019 Jan;29(1):1-8
pubmed: 29880235
J Neurooncol. 2016 Jan;126(1):19-26
pubmed: 26476730
Science. 2005 Mar 18;307(5716):1735-9
pubmed: 15774750
Onco Targets Ther. 2017 Feb 24;10:1115-1122
pubmed: 28280352
Cancer Sci. 2017 Jan;108(1):32-41
pubmed: 27754579
Mol Cell Biol. 2015 Aug;35(16):2851-63
pubmed: 26055329
Oncotarget. 2015 Sep 15;6(27):23708-19
pubmed: 26247633
Biomolecules. 2019 Feb 07;9(2):
pubmed: 30736436
Int J Biochem Cell Biol. 2013 Oct;45(10):2136-46
pubmed: 23764619
Cancer Biol Med. 2017 Nov;14(4):348-362
pubmed: 29372101
Pathol Res Pract. 2018 Dec;214(12):2062-2068
pubmed: 30477642
Oncol Lett. 2015 Oct;10(4):2283-2288
pubmed: 26622835
Protein Sci. 2013 Jan;22(1):1-10
pubmed: 23139046
Curr Genet. 2019 Feb;65(1):79-85
pubmed: 29926159
PLoS One. 2015 Nov 24;10(11):e0142596
pubmed: 26599082
Neoplasia. 2008 Mar;10(3):287-97
pubmed: 18320073
J Cell Biochem. 2019 Apr;120(4):5232-5243
pubmed: 30378152
Oncotarget. 2014 Sep 15;5(17):7446-57
pubmed: 25277184
Oncol Res. 2017 Mar 13;25(3):381-388
pubmed: 27662486
Cancer Res. 2005 Jun 1;65(11):4683-9
pubmed: 15930286
J Exp Clin Cancer Res. 2019 Feb 6;38(1):57
pubmed: 30728039
Biomed Pharmacother. 2018 Mar;99:59-64
pubmed: 29324313
Oncogene. 2006 Nov 2;25(52):6901-14
pubmed: 16732327
Cell Death Dis. 2018 Sep 5;9(9):908
pubmed: 30185771
PLoS Biol. 2018 Nov 8;16(11):e3000051
pubmed: 30408026
BMC Cancer. 2015 Jun 16;15:470
pubmed: 26077989
Mol Cell. 2005 Mar 4;17(5):721-32
pubmed: 15749021
Pathol Res Pract. 2018 Aug;214(8):1130-1135
pubmed: 29929749
Nat Rev Microbiol. 2005 Oct;3(10):799-808
pubmed: 16175175
Oncol Res. 2017 Apr 14;25(4):551-558
pubmed: 27737724
Nat Rev Mol Cell Biol. 2010 Dec;11(12):849-60
pubmed: 21102610
Cancer Biomark. 2017 Sep 7;20(3):309-315
pubmed: 28946563
J Cell Sci. 2017 Mar 15;130(6):1194
pubmed: 28298613
Oncogene. 2018 Jan 25;37(4):478-488
pubmed: 28967907
CA Cancer J Clin. 1994 May-Jun;44(3):133-5
pubmed: 7621066
Oncol Res. 2017 May 24;25(5):691-699
pubmed: 28244856
Cancer Lett. 2018 Oct 28;435:10-22
pubmed: 30075204
Genetics. 2014 Dec;198(4):1535-58
pubmed: 25261698
Cancer Sci. 2018 Dec;109(12):3840-3852
pubmed: 30238687
Biochem Biophys Res Commun. 2015 Jul 31;463(3):458-65
pubmed: 26043685
Cancer Cell Int. 2019 Mar 14;19:57
pubmed: 30918473
Oncotarget. 2018 Feb 5;9(17):13565-13581
pubmed: 29568378
J Cell Mol Med. 2018 Oct;22(10):5020-5028
pubmed: 30079558
Nat Cell Biol. 2011 Oct 03;13(10):1154-60
pubmed: 21968988
PLoS Pathog. 2008 Feb 8;4(2):e16
pubmed: 18248090
Int J Clin Oncol. 2016 Oct;21(5):927-933
pubmed: 27095111
Clin Lymphoma Myeloma Leuk. 2015 Feb;15(2):115-127.e15
pubmed: 25248926
EMBO J. 2001 May 1;20(9):2140-51
pubmed: 11331580
Cell Cycle. 2012 Feb 1;11(3):511-23
pubmed: 22262183
Genes Dev. 2012 Mar 15;26(6):542-7
pubmed: 22426531
Eur Rev Med Pharmacol Sci. 2016 Dec;20(23):4864-4873
pubmed: 27981550
Oncol Rep. 2018 Sep;40(3):1251-1260
pubmed: 29956813
Nat Rev Immunol. 2008 Nov;8(11):849-60
pubmed: 18836477
Int J Biochem Cell Biol. 2016 Oct;79:469-477
pubmed: 27458054
Cell Death Dis. 2018 May 22;9(6):608
pubmed: 29789583
Cancer Res. 2014 Oct 1;74(19):5620-30
pubmed: 25100564

Auteurs

Santina Venuto (S)

Division of Medical Genetics, Fondazione IRCCS Casa Sollievo della Sofferenza, Viale Padre Pio, 71013 San Giovanni Rotondo, Foggia, Italy. venutosantina@gmail.com.
PhD Program, Experimental and Regenerative Medicine, University of Foggia, Via A. Gramsci, 89/91, 71122 Foggia, Italy. venutosantina@gmail.com.

Giuseppe Merla (G)

Division of Medical Genetics, Fondazione IRCCS Casa Sollievo della Sofferenza, Viale Padre Pio, 71013 San Giovanni Rotondo, Foggia, Italy. g.merla@operapadrepio.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH